摘要
目的低巨核细胞性血小板减少症是临床上难治、易见的血小板减少性疾病,对大剂量丙种球蛋白、皮质激素、免疫抑制剂治疗效果不佳。方法 我们对2007年至2010年在我科住院的24例患者用重组人白介素-11治疗,以探讨该类疾病更好的治疗方法。结果 接受治疗的24例患者中,14例ITP患者治疗后达完全治疗反映4例,部份治疗反映5例,无效5例。CAA患者5例,治疗后达完全治疗反映1例,部份治疗反映1例,无效3例。急性白血病化疗后骨髓抑制5例,治疗后均达完全治疗反映。无效的5例ITP患者中有2例分别在病程第11个月、及2年6个月发展为再生障碍性贫血。结论 (1)对化疗药物引起的骨髓抑制使用白介素-11治疗可快速提升血小板,减轻化疗后骨髓不应期带来的出血。(2)对低巨核细胞性ITP有效率亦能达到64%,对该类患者如果常规治疗药物效果不佳,使用白介素-11治疗不失为一种不错的治疗手段。(3)对CAA的治疗有效率为40%,相对较差。
Objective The low megakaryocytes thrombocytopenia is a common thrombocytopenic disease but very difficult to cure.The therapy effect of high-dose immunoglobulin,cortical hormoneo and immunosuppressant is not so efficient.Methods We try to explore a better therapy to such kind of disease through recombinant human interleukin -11 to the 24 patients hospitalized in our hospital from 2007～2010.Results Among the 24 patients treated,14 patients with ITP fully reflected in 4 cases,5 cases partly reflected,5 cases is invalid.There are 5 cases of CAA patients,after treatment,1 reflected fully 1 partly reflected and 3 cases failed.After treatment through acute leukemia chemotherapy,5 cases are fully reflected.Invalid 5 cases of patients with ITP 2 developed into aplastic anemia in the sixth month and 18th month.Conclusion To the marrow inhibition caused by chemotherapy drug treatment,interleukin -11 may increase bloodcell and reduce bleeding after chemotherapy.To the ITP megakaryocytes,the effective rate achieve 64%.To such patients if routine treatment is not so efficient,the use of interleukin-11 therapy is a good treatments.The efficiency of CAA treatment is 40%,its effect is relatively poor.
出处
《中外医疗》
2011年第12期55-56,共2页
China & Foreign Medical Treatment
